Notice NOT-DC-19-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-018 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-18-509 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the Coordinating Center (TNCC) that is currently supporting the research being performed by the Type 1 Diabetes TrialNet network. This FOA will support the TNCC in its oversight of the screening of relatives of individuals with type 1 diabetes (T1D) for monitoring and possible inclusion in intervention studies aimed at preservation of insulin-producing cells. The FOA will also support the TNCC in its design, conduct and continuation of intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D (as selected by the TrialNet Steering Committee). The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination, and public accessibility. The TNCC will also provide capitated payments, based on TrialNet-related activities, to Clinical Centers and Affiliate Sites. In addition, the TNCC will be responsible for issuing a Request for Proposals (RFP) to select Clinical Centers to conduct TrialNet clinical studies.

Funding Opportunity RFA-DK-18-008 from the NIH Guide for Grants and Contracts. This FOA invites applications to fund continuation of the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit. The main objective of the HUB is to develop creative approaches to screening, recruitment, and trial implementation, and to increase the operational efficiency and flexibility of the TrialNet network.

Notice NOT-OD-19-057 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-032 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.

Funding Opportunity RFA-CA-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA solicits U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Negotiable: Paramount Recruitment: Vice President of Bioinformatics Paramount is currently searching for a dynamic, senior bioinformatics leader for one of the country's fasted growing biotechs. Stevenage, England

Negotiable: Paramount Recruitment: Data Scientists - Drug Discovery - Post-Doc Level One of the world's most prestigious pharmaceutical companies is expanding their drug discovery research facility and seeking a talented Bioinformatics, Data Scientists, Machine Learning Enthusiasts, Sta Oxfordshire, England

Negotiable: Paramount Recruitment: Bioinformatics Post-Docs - Cancer Diagnostics Paramount have two fantastic opportunities for Bioinformatics/Comp Bio/Data Science/Statistical Genetic Cambridge, England

Funding Opportunity RFA-RM-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects that will rapidly and systematically implement new technologies into the HuBMAP Consortium with the goal of accelerating development of a framework for mapping of the human body at single cell resolution. The scope of this FOA encompasses a wide range of technologies, spanning the fields of tissue collection and preservation; high resolution, high content, high-throughput imaging; high sensitivity and high specificity transcriptomics, genomics and proteomics; analysis, and visualization and modelling of multidimension biomolecular data.

Funding Opportunity PAR-19-162 from the NIH Guide for Grants and Contracts. The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old repeatedly for 10 years and makes that data available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).

Funding Opportunity PAR-19-163 from the NIH Guide for Grants and Contracts. The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old repeatedly for 10 years and makes that data available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).

Notice NOT-OD-19-046 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-056 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Scientific Software Developer - Python (Bioinformatics) A new opportunity is now available for a Scientific Software Developer to join a unique start-up company based in Cambridge, working in the field of Genomics and Bioinformatics. Cambridge, England

Competitive Salary: EMBL: Bioinformatics Cloud Architect Location: Cambridge, Cambridgeshire, England

Funding Opportunity RFA-DA-19-022 from the NIH Guide for Grants and Contracts. Develop and test a prototype mobile/tablet technology-based application suitable for U.S. primary care settings, to serve as a low-cost user-friendly tool that primary care providers (PCPs) may use to deliver timely tailored feedback to patients following up on interventions for risky substance use. The feedback delivered should make sure patients engage in appropriate self-monitoring and self-management skills in adherence to treatment plans delivered during interventions for problematic substance use. Patients answers should inform delivery of tailored feedback (matching level of problematic substance-use risk as determined by validated screening and assessment tools) supporting health-promotion behaviors, such as helping patients adhere to evidence-based motivational interviewing or other behavioral therapy principles. The application also should track health action items completed, such as linkage to indicated follow-up treatment. It should be designed with a specific aim of improving coordination and delivery of indicated services to primary care patients at risk of developing substance use disorders (SUD).